Multidisciplinary Obesity Care Programme With Semaglutide and Behavioral Treatment in Adults
Tests a team-based obesity care programme, including semaglutide, in adults living with obesity.
Plain-language title generated from the registry record
Registry title: OBESIAL: A Prospective Interventional Real-world Study of a Multidisciplinary Obesity Management Programme
Key facts
- Where
- Algiers, AlgeriaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT07779343, who can take part
Where in Algeria
- Department of Medicine, , Mother and Child Hospital of the Army (MCHA), Algiers University Hospital, Algiers, Algeria.Algiers, AlgeriaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Health Sciences, Algeria
- Trial code
- NCT07779343
- Record updated
- 21 August 2026
- Original description
The OBESIAL (Obesity Structured Intervention in Algeria) study aims to evaluate the clinical, metabolic, and organisational impact of a structured multidisciplinary obesity care pathway implemented under real-world conditions.Read full original descriptionShow less
OBESIAL: A Prospective Interventional Real-world Study of a Multidisciplinary Obesity Management Programme
The OBESIAL (Obesity Structured Intervention in Algeria) study aims to evaluate the clinical, metabolic, and organisational impact of a structured multidisciplinary obesity care pathway implemented under real-world conditions.
Inclusion: Adults aged 18-65 years; BMI ≥30 kg/m²; Written informed consent obtained prior to enrolment.
Exclusion: Previous bariatric surgery; Obesity pharmacotherapy within the previous 90 days; Severe or unstable comorbidities compromising safety or participation, including:; Recent acute cardiovascular event (<60 days); Active malignancy; Severe unstable organic disease; Severe unstable psychiatric disorders; Genetic obesity or obesity secondary to uncontrolled endocrine disease; Refusal to participate or inability to adhere to follow-up procedures; Pregnancy at enrolment; Known contraindication to planned therapeutic options; Pregnancy occurring during follow-up; Initiation of chronic treatment associated with weight gain.